Insys Therapeutics (INSY) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St set for higher open as soft inflation data eases rate-hike fears
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- HPE raises networking revenue outlook, secures $1.2B Vultr order
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
INSYS Therapeutics Reports First Quarter 2018 Results
May 8, 2018 4:00 PM EDTCannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS® revenue continue
PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its first quarter ended March 31, 2018.
OVERALL HIGHLIGHTS
Achieved gross revenue in first quarter of $38.5 million, down 26% versus prior year driven by decline in overall TIRF market.Net revenue in first quarter... More